Elizabeth Grosen, MD
Gynecologic Oncology · Spokane, WANPI 1235125220
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by AstraZeneca at 56.0% of the total. Reporting peaked in 2021 at $1,758 and has fallen 99.1% since, to $17 in 2025.
Across 21 payments — averaging $149.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Intuitive Surgical$621
- Tesaro, Inc.$221
- Seagen Inc.$125
- Foundation Medicine, Inc.$102
- Clovis Oncology, Inc.$99
- plus $209 from 5 others
Across 1 payment — averaging $10,728 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$11K
What the payments were for
- Consulting fees$1,66553%
- Speaking & faculty fees$1023%
- Travel & lodging$381%
- Food & beverage$1,01932%
- Education$993%
- Gifts$2137%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $1,758 |
| Intuitive Surgical | 8 | $621 |
| Tesaro, Inc. | 2 | $221 |
| Seagen Inc. | 1 | $125 |
| Foundation Medicine, Inc. | 1 | $102 |
| Clovis Oncology, Inc. | 1 | $99 |
| Myriad Genetic Laboratories, Inc. | 1 | $94 |
| Merck | 2 | $49 |
| Eisai Inc. | 1 | $36 |
| Caris MPI, Inc. | 1 | $17 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$1,665
- Da Vinci Surgical System$321
- TIVDAK$125
- ZEJULA$125
- FOUNDATIONONE$102
- FOUNDATIONONE HEME$102
- FOUNDATIONONE CDX$102
- FOUNDATIONFOCUS$102
- FOUNDATIONONE LIQUID$102
How this compares
$3,136 in reported general payments places this provider in the 70th percentile of 36 gynecologic oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $123 |
| Oxycodone Hcl | 12 | $86 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Spokane
- Melanie BergmanSpokane$967
- Susannah MourtonSpokane$778
- Casey HaySpokane$526
- Chirag ShahSeattle$732K
- Fernanda MusaSeattle$120K
- Bobbie RimelSeattle$41K
- Nicole FlemingSeattle$20K
- Kristin TaylorEverett$12K
- Renata UrbanSeattle$7K
- Robert OreLacey$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.